Seeking Alpha
Seeking Alpha Portfolio App for iPad
Finance
(1)
Market Currents

Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox...

  • Tuesday, January 22, 8:59 AM ET
    Celsion (CLSN) jumps 12.9% after signing a technology development agreement for its ThermoDox liver-cancer treatment with China's Hisun, which will pay $5M upfront and manufacture the drug. The deal is a precursor to a China licensing agreement that could be worth hundreds of millions of dollars to Celsion, and comes ahead of the results of Phase III trials for ThermoDox. (PR)
Track new comments on this story

This news story has 5 comments:

  •  
    Wow. Hisun's pretty early on this.... they must have something on the Phase 3's to be that confident to put down that kind of call option.
    22 Jan, 09:06 AM Reply Like
  •  
    Yeah, right. This is peanuts and a weak attempt by management to generate some positive PR. Only the data knows.
    22 Jan, 09:15 AM Reply Like
  •  
    Exactly.
    22 Jan, 09:19 AM Reply Like
  •  
    There is no reason to think the data will not be positive as the research results to date have continually supported each phase , this agreement . Hisun will make the product and it will be used worldwide.
    22 Jan, 09:53 AM Reply Like
  •  
    Agree, sounds a lot like hype
    22 Jan, 10:40 AM Reply Like
LATEST|
TODAY SO FAR|
YESTERDAY
Other date
DJIA (DIA) S&P 500 (SPY)

HEALTHCARE ETFs IN FOCUS

Latest Healthcare Articles
More Latest Articles »